941-P: Association of Incidence of Urinary Tract Infections (UTI) and Genitourinary Tract Infections (GTI) with Duration of SGLT2i in Type 2 Diabetes Mellitus Patients—A Pan-India Study

Introduction 6 months, 6-12 months, 12 months. The association between incidence and duration of SGLT2i groups was tested using Chi-square test. Results: Out of the total sample of 9,312 patients, 5,469 were males, and 3,843 were females. The sample breakdown based on the duration of SGLTi use revealed that 3,353 patients used it for 6 months, 2,509 for 6-12 months and 3,450 for 12 months. The average age was 55 years. The incidence of UTI varied across the duration groups, with rates of 8%, 5.1%, and 2.7% for 6 months, 6-12 months, and 12 months, respectively. These findings suggest a higher occurrence of UTI in the initial months of SGLT2i drug initiation, followed by a subsequent reduction in incidence with prolonged drug use. Conversely, no significant differences were observed in the occurrence of GTI across the duration groups, with rates of 4.7%, 4.7%, and 4.1% for 6 months, 6-12 months, and 12 months, respectively. Conclusion: As the duration of SGLT-2i treatment increases, there is a reduction in the incidence of UTI. Disclosure A.N. Singh: None. N.K. Singh: None. A. Gupta: None. S.R. Phatak: None.